Company Encyclopedia
View More
name
CHANGMAO BIO
00954.HK
Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, the United States, and internationally. The company offers maleic anhydride, fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L (+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame that are used as food additives, medical intermediaries, pharmaceutical adjuvant, active pharmaceutical ingredient, etc. It is also involved in the research and development of medicine and nutraceutical products; trading of organic acids; manufacture and sale of organic acid products; general trading; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou City, the People's Republic of China.
226.26 B
00954.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Specialty ChemicalsIndustry
Industry Ranking14/15
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-12.64%D
    • Profit Margin-13.85%D
    • Gross Margin4.83%E
  • Growth ScoreD
    • Revenue YoY-16.84%E
    • Net Profit YoY30.86%B
    • Total Assets YoY-1.27%D
    • Net Assets YoY-10.31%D
  • Cash ScoreE
    • Cash Flow Margin-721.98%E
    • OCF YoY-16.84%E
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreC
    • Gearing Ratio54.68%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CHANGMAO BIO announced its interim results, with a loss attributable to shareholders of 25.79 million yuan, an increase of 37.28% year-on-year

    CHANGMAO BIO announced its mid-year results for 2025, with revenue of approximately 272 million yuan, a year-on-year decrease of 13.23%; the loss attributable to shareholders of the company was 25.79 million yuan, a year-on-year increase of 37.28%; the loss per share was 0.049 yuan. The decline in performance was mainly affected by external factors such as geopolitical conflicts and uncertainty in tariff policies, as well as lower-than-expected demand for downstream products of maleic anhydride and increased interest expenses

    Zhitong·
    HK
    00954
    0.00%
    Zhitong·
    HK
    00954
    0.00%

    CHANGMAO BIO issues a profit warning, expecting a mid-term net loss of approximately 24 million to 27 million yuan

    CHANGMAO BIO issued a profit warning, expecting a consolidated net loss attributable to the company's shareholders of approximately RMB 24 million to 27 million for the six months ending June 30, 2025, an increase from the loss of RMB 18.786 million for the six months ending June 30, 2024. The board pointed out that the financial performance was affected by factors such as declining product sales prices, intensified market competition, and increased interest expenses

    Zhitong·
    HK
    00954
    0.00%
    Zhitong·
    HK
    00954
    0.00%

    "Profit Warning" CHANGMAO BIO is expected to have a mid-term loss expanded to approximately RMB 24 million to 27 million

    CHANGMAO BIO issued a profit warning, expecting to record a consolidated net loss of approximately RMB 24 million to 27 million for the interim period ending June 30, 2025, compared to a net loss of approximately RMB 18.786 million for the same period in 2024. This is mainly due to a decline in product sales prices and intense market competition, leading to a decrease in sales revenue and gross profit, as well as an increase in interest expenses included in the consolidated income statement

    AASTOCKS·
    HK
    00954
    0.00%
    AASTOCKS·
    HK
    00954
    0.00%

    CHANGMAO BIO's subsidiary signs a sale-leaseback contract for the machinery and equipment of the phthalic anhydride production line

    CHANGMAO BIO's wholly-owned subsidiary Changmao Dalian signed a sale-leaseback agreement with Changzhou Xinhui Financing Leasing Co., Ltd., involving maleic anhydride production line machinery and equipment. Changmao Dalian transferred leasing assets for approximately 50 million yuan and leased them back for approximately 57.531 million yuan, with a lease term of 48 months. Upon expiration of the lease term, if there is no default, the lessor will transfer the ownership of the assets back to Changmao Dalian in their current condition

    Zhitong·
    HK
    00954
    0.00%
    Zhitong·
    HK
    00954
    0.00%

    CHANGMAO BIO: Rui Xiaoqian will be appointed as Executive Director

    CHANGMAO BIO announced that Zeng Xianbiao and Wang Jianping resigned from their positions as non-executive directors for personal reasons, effective from June 18, 2025. The company's nomination committee and board of directors have approved Rui Xiaoqian as an executive director and Lin Zeyu as a non-executive director, with a term of three years, until June 17, 2028

    Zhitong·
    HK
    00954
    0.00%
    Zhitong·
    HK
    00954
    0.00%
    © 2025 Longbridge｜Disclaimer